Showing results (331-340 of 355) with videos related to
Sort By:
Pageof 36
Theriogenology|April 14, 2018
How does the microbial load affect the quality of equine cool-stored semen?E Varela, J Rey, E Plaza, et al.American Journal of Human Genetics|June 23, 1998
A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotypeP Guldberg, F Rey, J Zschocke, et al.Journal of Community Health|April 5, 2013
Predictors of hypertension among Filipino immigrants in the Northeast USRhodora A Ursua, Nadia Shilpi Islam, David E Aguilar, et al.Bone Marrow Transplantation|June 14, 2006
A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphomaD Coso, C Sebban, O Boulat, et al.American Journal of Respiratory and Critical Care Medicine|August 29, 2009
Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in ratsTimothy van Haaften, Roisin Byrne, Sebastien Bonnet, et al.Epilepsia|March 1, 2017
Laser thermal ablation for mesiotemporal epilepsy: Analysis of ablation volumes and trajectoriesWalter J Jermakowicz, Andres M Kanner, Samir Sur, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 2022
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete responseS Loibl, A Schneeweiss, J Huober, et al.Neurology. Clinical Practice|September 28, 2020
Cognitive outcomes following laser interstitial therapy for mesiotemporal epilepsiesChristin I Bermudez, Walter J Jermakowicz, John Paul G Kolcun, et al.ESMO Open|June 11, 2026
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA studyM Schmidt, M Thill, J Rey, et al.European Journal of Haematology|November 30, 2023
Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patientsC Petit, C Saillard, B Mohty, et al.Pageof 36